TY  - JOUR
AU  - Santiago-O'Farrill, Janice M
AU  - Weroha, S John
AU  - Hou, Xiaonan
AU  - Oberg, Ann L
AU  - Heinzen, Ethan P
AU  - Maurer, Matthew J
AU  - Pang, Lan
AU  - Rask, Philip
AU  - Amaravadi, Ravi K
AU  - Becker, Sarah E
AU  - Romero, Ignacio
AU  - Rubio, Ma Jesús
AU  - Matias-Guiu, Xavier
AU  - Santacana, Maria
AU  - Llombart-Cussac, Antonio
AU  - Poveda, Andrés
AU  - Lu, Zhen
AU  - Bast, Robert C
PY  - 2019
DO  - 10.1002/cncr.32600
UR  - http://hdl.handle.net/10668/14674
T2  - Cancer
AB  - Poly(adenosine diphosphate ribose) polymerase (PARP) inhibitors exhibit promising activity against ovarian cancers, but their efficacy can be limited by acquired drug resistance. This study explores the role of autophagy in regulating the sensitivity...
LA  - en
KW  - autophagy
KW  - ovarian cancer
KW  - poly(adenosine diphosphate ribose) polymerase (PARP) inhibitors
KW  - resistance
KW  - Animals
KW  - Antineoplastic Agents
KW  - Apoptosis
KW  - Autophagy
KW  - Cell Line, Tumor
KW  - Chloroquine
KW  - Drug Resistance, Neoplasm
KW  - Drug Synergism
KW  - Female
KW  - Humans
KW  - Indazoles
KW  - Mice, Nude
KW  - Mice, SCID
KW  - Ovarian Neoplasms
KW  - Phthalazines
KW  - Piperazines
KW  - Piperidines
KW  - Poly(ADP-ribose) Polymerase Inhibitors
KW  - Poly(ADP-ribose) Polymerases
KW  - Xenograft Model Antitumor Assays
TI  - Poly(adenosine diphosphate ribose) polymerase inhibitors induce autophagy-mediated drug resistance in ovarian cancer cells, xenografts, and patient-derived xenograft models.
TY  - research article
VL  - 126
ER  -